Massivemarkets

OCUL

Ocular Therapeutix, Inc.

Nasdaq · usd

$6.68-0.17 (-2.48%)
As of 12:48:38 PM EST on Nov 10, 2026 · 15-minute delayed

Ocular Therapeutix, Inc. (OCUL) trades at $6.68 (-2.48%) as of 12:48:38 PM EST on Nov 10, 2026, -12.17% over the past month. Market cap is $1.51B, with 8.1 days to cover in short interest.

Stock performance

How Ocular Therapeutix, Inc. (OCUL) stock has performed from one day to one year, with its 52-week range.

-4.56%
-$0.32 over 1D
$6.65$6.76$6.87$6.987:10 AM9:40 AM10:45 AM11:45 AM12:45 PM$6.69
1D
-3.07%
1W
-2.64%
1M
-12.17%
YTD
-45.30%
1Y
-40.82%
52-wk range
$6.00 – $16.44

Key statistics

Today's trading snapshot for OCUL: day range, open, previous close, volume and market cap.

Day range
$6.60 – $6.87
Open
$6.86
Prev close
$6.85
Volume
1.03M
Market cap
$1.51B
Shares out
219.62M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for Ocular Therapeutix, Inc.: P/E, P/S, P/B, ROE and more.

P/E
—
P/S
28.94
P/B
2.90
P/FCF
—
ROE
-58.0%
ROA
-44.9%
Debt/Equity
0.14
Div yield
0.00%

As of Nov 9, 2026

8-K filings

Material corporate events Ocular Therapeutix, Inc. has disclosed to the SEC on Form 8-K.

  • Director departureNov 9, 2026

    On November 6, 2026, Seung Suh Hong, Ph.D., notified the Company of his resignation from the Board, effective December 31, 2026. Dr. Hong's resignation is not the result of any disagreement with the Board or with management on any matter relating to the Company's operations, policies or practices.

  • On November 9, 2026, Ocular Therapeutix, Inc. announced its financial results for the quarter ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

  • On October 14, 2026, Sanjay Nayak, M.B.B.S., Ph.D., Chief Strategy Officer of Ocular Therapeutix, Inc. (the "Company"), notified the Company of his resignation from the Company, effective October 16, 2026, to become the Chief Executive Officer of a privately-held company.

  • Executive compensation changeJun 12, 2026

    Additionally, the Company granted Mr. Robins, effective June 10, 2026 (the 'Grant Date'), (i) a stock option to purchase up to 14,024 shares of the Company's common stock at a per share exercise price equal to the closing price of the Company's common stock on The Nasdaq Global Market on the Grant Date and (ii) a restricted stock unit award representing the right to receive 15,441 shares of the Company's common stock. Subject to Mr. Robins' continued service to the Company, his option award vests in equal monthly installments over a four-year period, and his restricted stock unit award vests in equal yearly installments over a three-year period.

  • Investor presentationFeb 27, 2026

    Ocular Therapeutix, Inc. (the "Company") will make available under the Investors section of its corporate website the slides to be presented by the Company at the 49th Macula Society Annual Meeting on February 27, 2026

OCUL short interest

How heavily OCUL is shorted: shares short, days to cover and average daily volume.

Days to cover
8.1
Short interest
28.76M
Avg volume
3.55M

As of · reported to FINRA twice monthly.

OCUL news

The latest news and headlines about Ocular Therapeutix, Inc. (OCUL).

Frequently asked questions

What is the Ocular Therapeutix, Inc. (OCUL) stock price today?

Ocular Therapeutix, Inc. (OCUL) is trading at $6.68 (-2.48% on the day) as of 12:48:38 PM EST on Nov 10, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is Ocular Therapeutix, Inc.?

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye.

What is the short interest in OCUL?

As of Oct 15, 2026, OCUL has 28.76M shares short and 8.1 days to cover.

What exchange is OCUL listed on?

Ocular Therapeutix, Inc. (OCUL) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

Build with AI

Build an analysis of OCUL with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a OCUL analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.